First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of AMG 579 following a
single oral dose administration in healthy subjects (Part A) and in patients with
schizophrenia or stable schizoaffective disorder (Part B). The study in healthy subjects
(Part A) concluded, and following a protocol amendment, enrolled only patients with
schizophrenia or stable schizoaffective disorder (Part B).